2-甲氧基-N-(3-甲基-2-氧代-1,2,3,4-四氢喹唑啉-6-基)苯磺酰胺
2-甲氧基-N-(3-甲基-2-氧代-1,2,3,4-四氢喹唑啉-6-基)苯磺酰胺结构式
|
常用名 | 2-甲氧基-N-(3-甲基-2-氧代-1,2,3,4-四氢喹唑啉-6-基)苯磺酰胺 | 英文名 | PFI-1 |
|---|---|---|---|---|
| CAS号 | 1403764-72-6 | 分子量 | 347.389 | |
| 密度 | 1.4±0.1 g/cm3 | 沸点 | N/A | |
| 分子式 | C16H17N3O4S | 熔点 | N/A | |
| MSDS | 美版 | 闪点 | N/A |
|
The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition.
Oncotarget 6 , 34669-79, (2015) Inhibition of BET bromodomains (BRDs) has emerged as a promising cancer therapeutic strategy. Accordingly, inhibitors of BRDs such as JQ1 have been actively developed and some have reached clinical testing. However, the mechanisms by which this group of inhib... |
|
|
The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors.
Cell Death Dis. 5 , e1450, (2014) Endogenous c-MYC (MYC) has been reported to be a potential pharmacological target to trigger ubiquitous tumor regression of pancreatic neuroendocrine tumors (PanNETs) and lung tumors. Recently inhibitors of bromodomain and extra-terminal (BET) family proteins... |
期刊文献综述：
更多...